The peripheral CB₁ receptor antagonist JD5037 attenuates liver fibrosis via a CB₁ receptor/β-arrestin1/Akt pathway.

ABSTRACT:

Background and purpose

Liver fibrosis is a serious cause of morbidity and mortality worldwide and has no adequate treatment. Accumulating evidence suggests that cannabinoid CB₁ receptors regulate a variety of physiological and pathological processes in the liver, and blockage of CB₁ receptor signalling shows promise as a new therapy for several liver diseases. The aim of this study was to investigate the potential therapeutic effects of CB₁ receptors and a peripheral CB₁ receptor antagonist JD5037 in liver fibrogenesis.

Experimental approach

Liver samples from both humans and mouse models were investigated. The peripheral CB₁ receptor antagonist JD5037, β-arr1 wild type (β-arr1-WT) and β-arr1 knockout (β-arr1-KO) litterm

SUBMITTER: Tan S 

PROVIDER: S-EPMC7236068 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature